Rhythm Pops on Health Canada Nod

Health Canada approved Rhythm Pharmaceuticals' Imcivree for weight management in patients aged 4+ with acquired hypothalamic obesity. The approval is based on a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. Imcivree is also approved in the U.S., Europe, and the UK for other obesity-related indications.

Rhythm Pharmaceuticals (RYTM) received Health Canada approval for IMCIVREE (setmelanotide) to treat weight management in patients 4 years and older with acquired hypothalamic obesity. The approval follows a Phase 3 trial showing an 18.8% placebo-adjusted BMI reduction. IMCIVREE is the first targeted therapy for this condition in Canada.

Rhythm Pharmaceuticals (RYTM) announced Health Canada approval of IMCIVREE for weight management in patients 4+ with acquired hypothalamic obesity. The approval follows positive Phase 3 TRANSCEND trial results, showing 18.8% placebo-adjusted BMI reduction. IMCIVREE is the first targeted therapy for this indication in Canada.

Rhythm Pharmaceuticals (RYTM) presented new data at the 64th ESPE Meeting, showing positive results for setmelanotide in treating paediatric acquired hypothalamic obesity, including BMI reductions and improved metabolic indices. Analysts note this strengthens the company's clinical story but does not alter its near-term financial losses. The data may support future regulatory and reimbursement progress, with analysts projecting significant revenue growth by 2029.

Leerink initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating and $133 price target, citing its leadership in rare obesity treatments and growth prospects.

Rhythm Pharmaceuticals (RYTM) presented data at ESPE 2026 showing setmelanotide reduced BMI and improved cardiometabolic markers in paediatric hypothalamic obesity patients. Real-world data from France showed mean BMI reductions of 11.5% at 6 months and 9.0% at 18 months. Phase 3 analyses showed significant improvements in metabolic indices compared to placebo.